Equities

Anika Therapeutics Inc

Anika Therapeutics Inc

Actions
  • Price (EUR)16.30
  • Today's Change-0.300 / -1.81%
  • Shares traded--
  • 1 Year change-13.76%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 20:52 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Anika Therapeutics Inc had net income fall 456.34% from a loss of 14.86m to a larger loss of 82.67m despite a 6.67% increase in revenues from 156.24m to 166.66m.
Gross margin62.70%
Net profit margin-59.40%
Operating margin-58.90%
Return on assets-34.86%
Return on equity-43.31%
Return on investment-38.55%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Anika Therapeutics Inc fell by 13.46m. In addition, the company used more cash to support its operations than it earned, posting a cash flow loss of 1.79m. In addition the company used 5.43m on investing activities and also paid 6.32m in financing cash flows.
Cash flow per share-5.94
Price/Cash flow per share--
Book value per share12.24
Tangible book value per share11.51
More ▼

Balance sheet in USDView more

Anika Therapeutics Inc appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio5.34
Quick ratio3.78
Total debt/total equity0.00
Total debt/total capital0.00
More ▼

Growth rates in USD

SmartText is unavailable
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago
-295.71
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.